Reports
Global Brain Tumor Treatment Market Share, Size, Analysis, Growth, Forecast: By Treatment Method: Targeted Therapy, Chemotherapy, Immunotherapy, Others; By Indication: Pituitary Tumors, Meningioma, Glioblastoma, Others; By Treatment Channel: Public, Private; Regional Analysis; Market Dynamics; Supplier Landscape; 2023-2031
Global Brain Tumor Treatment Market Outlook
The global brain tumor treatment market reached a value of about USD 3.1 billion in 2022. The market is further expected to grow at a CAGR of about 10.9% during the forecast period of 2023-2031 to attain a value of around USD 7.9 billion by 2031.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Brain Tumor: Insights and Diagnostic
Brain tumor is among the less common types of cancer, accounting for nearly 2% of the cancers. While the incidence is lower than the other types, it is extremely difficult to treat, which makes it among the top five fatal diseases. For the treatment, it is important to locate the exact location of the tumor and its growth. The location of the tumor is important because it defines the difficulty level of the treatment.
The prevalence of brain cancer is on a rise, nearly 400,000 new cases are diagnosed every year, which is further necessitating the demand for the treatment market. Brain tumors can be of different grades and these grades can be segmented into grade 1, 2, 3, and 4. While grade 1 and 2 are low grade tumors, grades 3 and 4 are high-grade and could be fatal. These cancers can be of two types-non-cancerous (benign) brain tumors and cancerous (malignant) brain tumors.
The common symptoms of the disease include headaches, nausea, seizures or fits, changes in mental health and behaviour, partial paralysis, issues with vision or speech.
Market Segmentations
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Brain tumor refers to the abnormal growth of cells in the brain. These brain tumors can be of different types and sizes. Some can be benign or non-cancerous, while others can be malignant or cancerous. Some cancers begin in the brain and spread to the rest of the body and some cancers develop in other body parts and then reach the brain as secondary tumors.
Market by Treatment Method
- Targeted Therapy
- Chemotherapy
- Immunotherapy
- Others
Market Breakup by Indication
- Pituitary Tumors
- Meningioma
- Glioblastoma
- Others
Market Breakup by Treatment Channel
- Public
- Private
Market Breakup by Region
- North America
- United States of America
- Canada
- Europe
- United Kingdom
- Germany
- France
- Italy
- Others
- Asia Pacific
- China
- Japan
- India
- ASEAN
- Australia
- Others
- Latin America
- Brazil
- Argentina
- Mexico
- Others
- Middle East and Africa
- Saudi Arabia
- United Arab Emirates
- Nigeria
- South Africa
- Others
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Epidemiology of Brain Tumor
Brain tumor is a life-threatening disease. The epidemiology of brain tumor depends on various factors, including age and sex. The prevalence rate of the disease is fairly higher in men than women. However, the prevalence of non-malignant brain tumors is much higher in women than men, almost double. According to the recent data by American Cancer Society, the number of tumor cases, both primary and other tumors in the nervous system, in the United States was estimated to be around 24,160 with expected death count of 19,720. The tumor is more likely to occur in people above the age of 65.
Therapeutic Landscape
The type of therapy/treatment that the patient goes through depends on the type and grade of the tumor. The methods in brain tumor treatment market include surgery, chemotherapy, radiation therapy, targeted drug therapy, tumor treating fields, regular follow-up care and rehabilitation, among others. The most common treatment methods are as follows:
Targeted Therapy- This treatment attacks/targets the specific genes, proteins, or the tissue environment with the use of medicines. The two most preferred targeted therapies include Bevacizumab (Avastin, Mvasi), which is an anti-angiogenesis therapy, and Larotrectinib (Vitrakvi) and entrectinib (Rozlytrek), which leads to genetic change.
Chemotherapy – This treatment method is preferred for faster growing tumors where the blast rate is higher. The therapy comprises of drugs which are given either through veins or orally, depending on the state of the patient. Brain tumors like medulloblastoma and lymphoma respond much better to chemotherapy than others, however, there have been cases of other tumors where the drugs are not able to make it to the tumor or the brain. There are several chemo drugs which are currently used in the therapy, either alone or in combination with one another. These drugs include Cisplatin, Carmustine (BCNU), Cyclophosphamide, Etoposide, Carboplatin, Irinotecan, Methotrexate, Lomustine (CCNU), Procarbazine, and Temozolomide, among others.
Immunotherapy- This therapy stimulates the body’s immune system to attack the tumor cells to inhibit their growth. T cells, which are a type of immune cells, play a pivotal role in attacking the tumor cells in the brain. Immunotherapy aims at targeting and eliminating the cancer cells by activating anti-tumor response in the T cells. This method also helps in preventing relapse.
Clinical Trials
Reduced Craniospinal Radiation Therapy- This trial is currently in phase II and studies the effects of reduced doses of radiation therapy and chemotherapy in patients with WNT/Wingless (WNT)-driven medulloblastoma, a new type of brain tumor that has been recently discovered. The reduced doses can help attack the tumor cells without the same intensity of the side-effects that normally occur due to the heavy dosage of drugs used in these therapies, including difficulty in learning, reduced hormones, or problems in doing daily activities.
Early Response to Bevacizumab in Patients with Recurrent Glioblastoma- This study is also in phase II currently. It studies the effectiveness of dynamic susceptibility contrast-enhanced magnetic resonance imaging (DSC-MRI) in calculating the rCBV or relative cerebral blood volume for fast response to bevacizumab in patients with recurrent glioblastoma.
There are other ongoing clinical trials in the treatment market which are still under process and will likely be approved in the coming years.
Key Players in the Global Brain Tumor Treatment Market
The report gives a detailed analysis of the following key players in the global brain tumor treatment market, covering their competitive landscape, capacity, and latest developments like mergers, acquisitions, and investments, expansions of capacity, and plant turnarounds:
- Pfizer Inc.
- Novartis AG
- Merck & Co. Inc.
- AstraZeneca Plc.
- F. Hoffmann-La Roche Ltd.
- Amgen Inc.
- CordenPharma International
- Eisai Co., Ltd.
- Emcure Pharmaceuticals Limited
- Y-mAbs Therapeutics
- Bayer AG
- Bristol-Myers Squibb Co.
- GlaxoSmithKline Plc.
- Johnson & Johnson Services Inc.
The comprehensive EMR report provides an in-depth assessment of the market based on the Porter's five forces model along with giving a SWOT analysis.
Key Highlights of the Report
| REPORT FEATURES | DETAILS |
|---|---|
| Base Year | 2022 |
| Historical Period | 2016-2022 |
| Forecast Period | 2023-2031 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Treatment Method |
|
| Breakup by Indication |
|
| Breakup by Treatment Channel |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Competitive Landscape |
|
| Companies Covered |
|
*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.
1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
2 Research Methodology
3 Executive Summary
4 Brain Tumor Overview
4.1 Guidelines and Stages
4.2 Pathophysiology
4.3 Screening and Diagnosis
4.4 Treatment Pathway
5 Patient Profile
5.1 Patient Profile Overview
5.2 Patient Psychology and Emotional Impact Factors
5.3 Risk Assessment and Treatment Success Rate
6 Current Scenario Evaluation and Regulatory Framework
6.1 Emerging Therapies and Clinical Trials Synopsis
6.2 Patent Landscape
6.2.1 Patent Overview
6.2.1.1 Patent Status and Expiry
6.2.1.2 Timelines from Drug Development to Commercial Launch
6.2.1.3 New Drug Application
6.2.1.3.1 Documentation and Approval Process
6.3 Cost of Treatment
6.4 Regulatory Framework
6.4.1 Regulatory Overview
6.4.1.1 US FDA
6.4.1.2 EU EMA
6.4.1.3 INDIA CDSCO
6.4.1.4 JAPAN PMDA
6.4.1.5 Others
7 Challenges and Unmet Need
7.1 Treatment Pathway Challenges
7.2 Compliance and Drop-Out Analysis
7.3 Awareness and Prevention Gaps
8 Global Brain Tumor Treatment Market
8.1 Global Brain Tumor Treatment Market Overview
8.2 Global Brain Tumor Treatment Market Analysis
8.2.1 Market Overview
8.2.1.1 Global Brain Tumor Treatment Market Historical Value (2016-2022)
8.2.1.2 Global Brain Tumor Treatment Market Forecast Value (2023-2031)
8.3 Global Brain Tumor Treatment Market by Treatment Method
8.3.1 Market Overview
8.3.1.1 Targeted Therapy
8.3.1.2 Chemotherapy
8.3.1.3 Immunotherapy
8.3.1.4 Others
8.4 Global Brain Tumor Treatment Market by Indication
8.4.1 Market Overview
8.4.1.1 Pituitary Tumors
8.4.1.2 Meningioma
8.4.1.3 Glioblastoma
8.4.1.4 Others
8.5 Global Brain Tumor Treatment Market by Treatment Channel
8.5.1 Public
8.5.2 Private
8.6 Global Brain Tumor Treatment Market by Region
8.6.1 Market Overview
8.6.1.1 North America
8.6.1.2 Europe
8.6.1.3 Asia Pacific
8.6.1.4 Latin America
8.6.1.5 Middle East and Africa
9 North America Brain Tumor Treatment Market
9.1 Market Share by Country
9.2 United States of America
9.2.1 Historical Trend (2016-2022)
9.2.2 Forecast Trend (2023-2031)
9.3 Canada
9.3.1 Historical Trend (2016-2022)
9.3.2 Forecast Trend (2023-2031)
10 Europe Brain Tumor Treatment Market
10.1 Market Share by Country
10.2 United Kingdom
10.2.1 Historical Trend (2016-2022)
10.2.2 Forecast Trend (2023-2031)
10.3 Germany
10.3.1 Historical Trend (2016-2022)
10.3.2 Forecast Trend (2023-2031)
10.4 France
10.4.1 Historical Trend (2016-2022)
10.4.2 Forecast Trend (2023-2031)
10.5 Italy
10.5.1 Historical Trend (2016-2022)
10.5.2 Forecast Trend (2023-2031)
10.6 Others
11 Asia Pacific Brain Tumor Treatment Market
11.1 Market Share by Country
11.2 China
11.2.1 Historical Trend (2016-2022)
11.2.2 Forecast Trend (2023-2031)
11.3 Japan
11.3.1 Historical Trend (2016-2022)
11.3.2 Forecast Trend (2023-2031)
11.4 India
11.4.1 Historical Trend (2016-2022)
11.4.2 Forecast Trend (2023-2031)
11.5 ASEAN
11.5.1 Historical Trend (2016-2022)
11.5.2 Forecast Trend (2023-2031)
11.6 Australia
11.6.1 Historical Trend (2016-2022)
11.6.2 Forecast Trend (2023-2031)
11.7 Others
12 Latin America Brain Tumor Treatment Market
12.1 Market Share by Country
12.2 Brazil
12.2.1 Historical Trend (2016-2022)
12.2.2 Forecast Trend (2023-2031)
12.3 Argentina
12.3.1 Historical Trend (2016-2022)
12.3.2 Forecast Trend (2023-2031)
12.4 Mexico
12.4.1 Historical Trend (2016-2022)
12.4.2 Forecast Trend (2023-2031)
12.5 Others
13 Middle East and Africa Brain Tumor Treatment Market
13.1 Market Share by Country
13.2 Saudi Arabia
13.2.1 Historical Trend (2016-2022)
13.2.2 Forecast Trend (2023-2031)
13.3 United Arab Emirates
13.3.1 Historical Trend (2016-2022)
13.3.2 Forecast Trend (2023-2031)
13.4 Nigeria
13.4.1 Historical Trend (2016-2022)
13.4.2 Forecast Trend (2023-2031)
13.5 South Africa
13.5.1 Historical Trend (2016-2022)
13.5.2 Forecast Trend (2023-2031)
13.6 Others
14 Global Brain Tumor Treatment Market Dynamics
14.1 Market Drivers and Constraints
14.2 SWOT Analysis
14.3 Porter’s Five Forces Model
14.4 Key Demand Indicators
14.5 Key Price Indicators
14.6 Industry Events, Initiatives, and Trends
14.7 Value Chain Analysis
15 Supplier Landscape
15.1 Pfizer Inc.
15.1.1 Company Overview
15.1.2 Product Portfolio
15.1.3 Demographic Reach and Achievements
15.1.4 Mergers and Acquisitions
15.1.5 Certifications
15.2 Novartis AG
15.2.1 Company Overview
15.2.2 Product Portfolio
15.2.3 Demographic Reach and Achievements
15.2.4 Mergers and Acquisitions
15.2.5 Certifications
15.3 Merck & Co. Inc.
15.3.1 Company Overview
15.3.2 Product Portfolio
15.3.3 Demographic Reach and Achievement
15.3.4 Mergers and Acquisitions
15.3.5 Certifications
15.4 AstraZeneca Plc.
15.4.1 Company Overview
15.4.2 Product Portfolio
15.4.3 Demographic Reach and Achievements
15.4.4 Mergers and Acquisitions
15.4.5 Certifications
15.5 F. Hoffmann-La Roche Ltd.
15.5.1 Company Overview
15.5.2 Product Portfolio
15.5.3 Demographic Reach and Achievements
15.5.4 Mergers and Acquisitions
15.5.5 Certifications
15.6 Amgen Inc.
15.6.1 Company Overview
15.6.2 Product Portfolio
15.6.3 Demographic Reach and Achievements
15.6.4 Mergers and Acquisitions
15.6.5 Certifications
15.7 CordenPharma International
15.7.1 Company Overview
15.7.2 Product Portfolio
15.7.3 Demographic Reach and Achievements
15.7.4 Mergers and Acquisitions
15.7.5 Certifications
15.8 Eisai Co., Ltd.
15.8.1 Company Overview
15.8.2 Product Portfolio
15.8.3 Demographic Reach and Achievements
15.8.4 Mergers and Acquisitions
15.8.5 Certifications
15.9 Emcure Pharmaceuticals Limited
15.9.1 Company Overview
15.9.2 Product Portfolio
15.9.3 Demographic Reach and Achievements
15.9.4 Mergers and Acquisitions
15.9.5 Certifications
15.10 Y-mAbs Therapeutics
15.10.1 Company Overview
15.10.2 Product Portfolio
15.10.3 Demographic Reach and Achievements
15.10.4 Mergers and Acquisitions
15.10.5 Certifications
15.11 Bayer AG
15.11.1 Company Overview
15.11.2 Product Portfolio
15.11.3 Demographic Reach and Achievements
15.11.4 Mergers and Acquisitions
15.11.5 Certifications
15.12 Bristol-Myers Squibb Co.
15.12.1 Company Overview
15.12.2 Product Portfolio
15.12.3 Demographic Reach and Achievements
15.12.4 Mergers and Acquisitions
15.12.5 Certifications
15.13 GlaxoSmithKline Plc.
15.13.1 Company Overview
15.13.2 Product Portfolio
15.13.3 Demographic Reach and Achievements
15.13.4 Mergers and Acquisitions
15.13.5 Certifications
15.14 Johnson & Johnson Services Inc.
15.14.1 Company Overview
15.14.2 Product Portfolio
15.14.3 Demographic Reach and Achievements
15.14.4 Mergers and Acquisitions
15.14.5 Certifications
16 Global Brain Tumor Treatment Market- Drug Distribution Model (Additional Insights)
16.1 Overview
16.2 Potential Distributors
16.3 Key Parameters for Distribution Partner Assessment
17 Payment Methods (Additional Insight)
17.1 Government Funded
17.2 Private Insurance
17.3 Out-of-Pocket
*Additional insights provided are customisable as per client requirements.
Key Questions Answered in the Report
In 2022, the global brain tumor treatment market attained a value of nearly USD 3.1 billion.
The market is projected to grow at a CAGR of 10.9% during the forecast period of 2023-2031.
The market is estimated to witness healthy growth during the forecast period of 2022-2031 to reach a value of USD 7.9 billion by 2031.
The growth of the market is driven by factors like rising prevalence of the disease, rapid technological advancements, availability of non-invasive therapies, and rising expenditure on healthcare.
The key trends in the market include rising research and development, along with the rising awareness about the availability and effectiveness of available treatment.
The major regions in the market are North America, Latin America, the Middle East and Africa, Europe, and the Asia Pacific.
Treatment channels include targeted therapy, chemotherapy, and immunotherapy, among others.
The segments based on indication pituitary tumors, meningioma, and glioblastoma, among others.
The treatment channels in the market include public and private.
The major players in the market are Pfizer Inc., Novartis AG, Merck & Co. Inc., AstraZeneca Plc., F. Hoffmann-La Roche Ltd., Amgen Inc., Eisai Co., Ltd., Emcure Pharmaceuticals Limited, Y-mAbs Therapeutics, Bayer AG, Bristol-Myers Squibb Co., GlaxoSmithKline Plc., Johnson & Johnson Services Inc., and CordenPharma International.
Purchase Options
Call us on
Purchase Full Report
Mini Report
$3499
-
Selected Sections, One User
-
Printing Not Allowed
-
Email Delivery in PDF
-
Free Limited CustomisationPost Sales Analyst Support50% Discount on Next UpdateSingle User License
$5999-
All Sections, One User
-
One Print Allowed
-
Email Delivery in PDF
-
Free Limited CustomisationPost Sales Analyst Support50% Discount on Next Update
Five User License
$7999-
All Sections, Five Users
-
Five Prints Allowed
-
Email Delivery in PDF
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Corporate License
$9999-
All Sections, Unlimited Users
-
Unlimited Prints Allowed
-
Email Delivery in PDF + Excel
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Contact AnalystAny Question? Speak With An Analyst
Request SampleView A Sample
Request CustomisationDid You Miss Anything, Ask Now
Why Expert Market Research?Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.
Similar Reports
NEWSLETTER